Shirish Gadgeel

Shirish Gadgeel contributed to the KEYNOTE-189 trial establishing pembrolizumab plus chemotherapy as a first-line standard of care for non-squamous NSCLC regardless of PD-L1 status. His clinical and translational research focuses on combination immunotherapy strategies, resistance mechanisms, and biomarker predictors of chemo-IO benefit. He has led thoracic oncology programs at major academic cancer centers and contributes to ASCO and NCCN clinical practice guidelines. Gadgeel is a recognized expert on optimal use of pembrolizumab-based combinations in the first-line NSCLC setting.